Page 1,588«..1020..1,5871,5881,5891,590..1,6001,610..»

If you’re serious about lowering your diabetes risk, you should eat this right now – Star2.com

Posted: April 12, 2017 at 7:42 am

New research has found that a diet rich in legumes could lower the risk of developing diabetes.

Legumes are already known to have various health benefits thanks to being rich in B vitamins, minerals (including calcium, potassium and magnesium) and fibre. Although they have long been thought to offer protection against type-2 diabetes there has been little research so far to confirm these beliefs.

To examine this association researchers from the Human Nutrition Unit at Universitat Rovira i Virgili (URV) in Spain collaborated with other research groups in the Prevention of Diabetes with Mediterranean Diets (Predimed) study.

Together the team looked at effects of different non-soy legumes lentils, chickpeas, beans and peas on the risk of type-2 diabetes among individuals at high cardiovascular risk.

A low intake of legumes was considered to be 12.73g a day, approximately equivalent to 1.5 servings per week of 60g of raw legumes.

A high intake consisted of 28.75g a day, equivalent to 3.35 servings per week.

The team also assessed what effect replacing other protein- and carbohydrate-rich foods with legumes had on the development of the disease.

A total of 3,349 participants were analysed from the Predimed study, all at high risk of cardiovascular disease but without type-2 diabetes when the study started.

After four years, the results showed that that compared to individuals with a lower consumption of legumes, those with a higher consumption had a 35% lower risk of developing type-2 diabetes.

Those who ate more legumes were found to have lower risk of type-2 diabetes.

Lentils in particular were associated with a lower risk of the condition, with participants who had a higher consumption of lentils (nearly 1 serving per week) benefiting from a 33% lower risk compared to those individuals with a lower consumption (less than half a serving per week).

The team also found that replacing half a serving per day of foods rich in protein or carbohydrates, including eggs, bread, rice and baked potato, with half a serving per day of legumes was associated with a lower risk of type-2 diabetes.

The researchers highlight the importance of consuming legumes to prevent chronic diseases such as diabetes, although they added that further research is needed in order to confirm their findings.

The Food and Agriculture Organization of the United Nations (FAO) also declared 2016 as the international year of legumes in an effort to raise peoples awareness of their nutritional benefits.

The results was published in the journal Clinical Nutrition. AFP Relaxnews

All comments are moderated. Your comment may not show up immediately. Please keep it clean and on topic. Offensive comments will not be published.

Read this article:
If you're serious about lowering your diabetes risk, you should eat this right now - Star2.com

Posted in Diabetes | Comments Off on If you’re serious about lowering your diabetes risk, you should eat this right now – Star2.com

Earnings Preview: Biotechnology Looks Healthy – Barron’s

Posted: April 11, 2017 at 3:44 pm


Barron's
Earnings Preview: Biotechnology Looks Healthy
Barron's
The iShares Nasdaq Biotechnology (IBB) has climbed 0.34%. Meanwhile the SPDR S&P Biotech ETF (XBI) has declined 0.21%. IBB could be benefiting from having a wider swath of companies, in addition to the fact that the average market cap of its index ...

and more »

Originally posted here:
Earnings Preview: Biotechnology Looks Healthy - Barron's

Posted in Biotechnology | Comments Off on Earnings Preview: Biotechnology Looks Healthy – Barron’s

Agricultural biotechnology regulations are a mess Here’s how Trump can unshackle innovation – Genetic Literacy Project

Posted: April 11, 2017 at 3:44 pm

[The following is the first part of anInformation Technology and Innovation Foundation report.]

New techniques for improving plants and animals promise to reshape virtually every aspect of the relationship between humans and our environment for the better. Safer and more sustainable crops have already made enormous contributions to the economy and the environment, and genetically improved livestock and companion animals are close behind. Discovery of more precise, predictable, and easily used techniques derived directly from nature is dramatically accelerating this progress. But fears of the new have led to calls in many nations for precautionary regulation, which risks stifling agricultural innovation without any showing of need or benefit. There is a better way. This report discusses proposals for updating policies and regulations for agricultural biotechnology products in the United States to ensure they safeguard

This report discusses proposals for updating policies and regulations for agricultural biotechnology products in the United States to ensure they safeguard public and environmental health and animal welfare without discouraging needed innovations. An authoritative review of 10 years worth of academic literature has found that the scientific research conducted so far has not detected any significant hazards directly connected with the use of [genetically engineered] crops. This experience is evidence that the time is long past due for significant regulatory rollback in this field around the world. Good advice has already been offered as to the best ways for updating these regulations. Not all of it has been followed yet, leaving numerous opportunities for improvement by the new administration. This report recommends the following reforms:

BACKGROUND The single biggest obstacle slowing the wider dissemination of the considerable benefits from agricultural biotechnology innovations is unwarranted regulatory burdens across the world. The disparity between the degree of hazard or risk associated with these innovations and the regulatory hurdles they must clear has widened everywhere over the past three decades from a gap to a chasm. This has happened even while experience has shown that early safety concerns were unfounded, and that the predictability and safety associated with these innovations has been shown to be unmatched by the products of any other production method.

What Is Agricultural Biotechnology and Why Should We Care? Innovations in agriculture are being delivered today through a host of different techniques referred to with a baffling array of labels: recombinant DNA, genetically modified organisms (GMOs), genetic modification (GM), gene editing, CRISPR, TALENs, Zinc Fingers, meganucleases, advanced breeding, new breeding technologies, precision agriculture, big data, remote sensing, and more. There is some overlap among these terms both vis--vis the subject matter they cover and the ways in which they are used, but misunderstanding is widespread, and scientific justification for some of these terms is lacking or altogether absent.

When scientifically nonsensical terms are used as the foundation of discriminatory regulations, without due regard for hazard or risk, the resulting policies do not advance the protection of public and environmental health. This is the case for any and all regulations that single out GM processes or GMOs for regulatory scrutiny. Scientists and policy mavens spent years examining these issues in the late 1970s and early 1980s. They reached consensus that the process of genetic modification tells regulators nothing useful about any possible hazards of the resulting product, or the risks associated with different levels of exposure; these require consideration of the final characteristics and qualities of a productits phenotype. To use an example from manufacturing, a products safety does not depend on how a chemical is made, but rather on its chemical composition and structure. The same is true for food, feed, fiber, and animal products. Yet, for ideological or political reasons unsupported by data or experience, many nations regulators have adopted explicitly process-based regulations. Even countries that have avoided this fundamental error have drifted in that direction through

Yet, for ideological or political reasons unsupported by data or experience, many nations regulators have adopted explicitly process-based regulations. Even countries that have avoided this fundamental error have drifted in that direction through uncritical implementation of otherwise less flawed regulations that slow ag-biotech innovation. These different developments have combined to create the gross disparity between and within nations regarding risk and regulatory burden as manifested in regulatory proposals we examine here.

GM Food Is Safe The foundation of confidence in the safety of agricultural products produced through biotechnology, no matter what breeding method was used, lies in a concept known as substantial equivalence. This is based on the work of an international expert group at the Organization for Economic Cooperation and Development (OECD), which published a series of landmark policy papers in the 1980s and 1990s. The concept of substantial equivalence emerged from the recognition that plants and animals we have long used for food provide a familiar baseline for comparison and for the evaluation of novel traits as we consider their safety. A number of factors are important, including:

The U.S. National Academy of Sciences explicitly endorsed this approach in its first paper on this topic, and reaffirmed it in 11 subsequent reports, which corroborated the safety of products produced with these methods. The safety of these products was reaffirmed in a comprehensive review of more than 1,700 peer-reviewed papers from the scientific literature over a decade, published in 2013, adding to a database of more than 2,000 such papers compiled by independent academics. It is noteworthy that based on their findings, independent academics and industry scientists reach identical conclusions. For these reasons, more than 275 scientific organizations have embraced the global scientific consensus on the safety of GM crops and foods. The European Union has summarized the safety issue thus:

Indeed, the use of more precise technology and the greater regulatory scrutiny probably make them even safer than conventional plants and foods; and if there are unforeseen environmental effectsnone have appeared as yetthese should be rapidly detected by our monitoring requirements. On the other hand, the benefits of these plants and products for human health and the environment become increasingly clear.

Process-Based Regulation Doesnt Work In the early 1980s, when the potential of recombinant DNA techniques to deliver solutions to problems in agriculture was first widely noted, two main schools of thought emerged on the best way to ensure their safety without discouraging innovation. Expert bodies around the world repeatedly found no unique or novel hazards associated with crops, livestock, microbes, or foods improved through biotechnology. They found that the foreseeable risks were similar to those with which we were long familiar with from classical plant and animal breeding throughout 10 millennia of domestication and agriculture. As a result, the United States, Canada, and Australia aimed to base regulations on experience and scientific data. U.S. policymakers, for example, concluded that existing regulations for risk assessment and management were sufficient, and determined to move forward with products of agricultural biotechnology under close scrutiny, with a watchful eye for surprises. This was attended by the expectation that regulations would be adapted regularly as knowledge and understanding accrued.

European politicians chose a different approach, and crafted new, process-specific regulations unrelated to any concrete demonstration of real hazards or actual risks, based instead on hypothetical potential harms. Following this lead, a number of other countries have also taken this precautionary approach and subordinated the findings of scientific risk assessment and experience to political and ideological interests. The results have been clear and dramatic; innovative products have rapidly swept to market dominance in countries that have chosen science-based approaches, while European farmers have become increasingly uncompetitive as innovators have fled the continent. The harshest condemnations of the failed European precautionary approach have come from Europeans.

But despite this reasoned approach early on, regulations in the United States more recently have not evolved to match our accumulated experience and the dramatic growth in our understanding. Regulations first laid down in 1987 have been significantly adapted to experience only once, in 1992. Since then, the disparity between the level of risk and the degree of regulation has expanded dramatically. This led the White House Office of Science and Technology Policy in 2015 to call for an updating of regulatory agencies responsibilities under the Coordinated Framework, the 1986 roadmap set forth to guide regulators into the new landscape. The new Trump administrations directive that each new regulation must be accompanied by repeal of two already in place is, in this arena at least, a step in the right direction.

The Purpose of Regulation Is to Manage Risk Regulations exist for a purpose: to manage and mitigate risks. Reasonable and effective regulations will also incorporate a consideration of economic costs and dynamic innovation effects. Thus, under the 1986 Coordinated Framework, the Animal and Plant Health Inspection Service is charged with managing risks that crops improved through biotechnology may present to American agriculture; the Environmental Protection Agency with ensuring that pesticides are used safely to manage pests and protect human and environmental health; and the Food and Drug Administration with ensuring that food and feed derived from crops or animals improved through biotechnology are as safe to consume as other food and feed.

But much of the oversight applied to crops improved through biotechnology in the United States has lost sight of the fundamental principle for determining risk, expressed in the equation: risk equals hazard times exposure. If there is no prospect for exposure to a hazard, then the hazard, no matter how great, presents no risk. If there is no hazard, or if it is present only at very low levels, then even high levels of exposure may be entirely irrelevant to human or environmental health. But in the regulatory systems now in place there is no relationship among the presence of a hazard, the level of exposure, and the degree of regulatory scrutiny applied. If innovation is to be enabled, much less encouraged, that must be remedied. But the importance of one other objective driving the adoption of regulations to deal with biotechnological innovations in agriculture cannot be overstated:

But the importance of one other objective driving the adoption of regulations to deal with biotechnological innovations in agriculture cannot be overstated:

In response to public concern [t]he goal in developing the Coordinated Framework was to explain to the American public that, for questions involving the products of biotechnology (more specifically, organisms derived from recombinant-DNA technology), human health and the health of the environment were of paramount concern and were adequately protected.

There is no denying the virtuous intent of that sentiment, for if consumers are not convinced that biotech foods are safe they will not buy them. But in fact, the promulgation of regulations in advance of any confirmed finding of hazard or demonstration of risk has not assuaged public concerns. Nor has the subsequent confirmation of safety led to areduction in regulatory oversight or regulatory delays in the deployment of innovative technologies and products. In fact, entrenched opposition from the very beginning has taken every emplacement of regulation as confirmation of the need for yet more stringent regulation, driven by the unfounded assertion of unique and technology-specific hazards.

This discordance between the degree of regulatory oversight and the actual hazards and risks confirmed by experience has only grown over the years, exacerbated by the emergence of regulation for the purpose of litigation-avoidance by the agencies. Special interest groups have brought a significant number of procedural lawsuits against USDA for approving specific crops improved through biotechnology, leading to lengthy delays in the dissemination of new products.23 The ephemeral success of these lawsuits hinged on deficiencies noted by the courts in the documentation of USDAs decision-making process. In no case have they identified any genuine hazard, and, after USDA repaired the paper record for its decision making, the products are now on the market. But the opportunity costs, both economic and environmental, imposed by the delays remain on the ledgers.

[Read the rest of the report here.]

This article originally appeared on The Information Technology and Innovation Foundations website under the title How the Trump Administration Can Unshackle Innovation in Agricultural Biotechnology and has been republished with permission from the author.

Val Giddings is Senior Fellow at the Information Technology & Innovation Foundation. He previously served as vice president for Food & Agriculture of the Biotechnology Industry Organization (BIO) and at the Congressional Office of Technology Assessment and as an expert consultant to the United Nations Environment Programme, the World Bank, USDA, USAID, and companies, organizations and governments around the world. Follow him on twitter @prometheusgreen.

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Visit link:
Agricultural biotechnology regulations are a mess Here's how Trump can unshackle innovation - Genetic Literacy Project

Posted in Biotechnology | Comments Off on Agricultural biotechnology regulations are a mess Here’s how Trump can unshackle innovation – Genetic Literacy Project

President of Senegal bucks anti-biotechnology pressure: ‘I am for the use of GMOs’ – Genetic Literacy Project

Posted: April 11, 2017 at 3:44 pm

President Macky Sall of Senegal has thrown his weight behind the adoption of agricultural biotechnology in the country.

.

President Sall made it clear that he supported the implementation of biotechnology in Senegal provided necessary measures to minimise risks were taken.

Macky Sall

I must say very clearly that I am for the use of GMOs based on the precautions taken and based on a dynamic regulation, otherwise we would be against progress. We must decide and step forward. We need to move forward because we have food security imperatives.

It is undeniable that GMOs can help meet current challenges, such as food insecurity, public health issues, natural resource conservation and climate change, he stressed.

We need serious thought to develop a strategy to maximise the use of GMOs, while mitigating the risks associated with them. That is why it is necessary to strengthen the National Biosafety Authority and to have an appropriate legal system combined with an efficient information system based on objective scientific values to assess the cost/benefit/risks ratio, he further stressed.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:GMOs: Senegal supports adoption of agric biotech

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Visit link:
President of Senegal bucks anti-biotechnology pressure: 'I am for the use of GMOs' - Genetic Literacy Project

Posted in Biotechnology | Comments Off on President of Senegal bucks anti-biotechnology pressure: ‘I am for the use of GMOs’ – Genetic Literacy Project

Puma Biotechnology, Inc. (PBYI) recently sold by insider CHARNAS ROBERT – Post Analyst

Posted: April 11, 2017 at 3:44 pm

Puma Biotechnology, Inc. (PBYI) recently sold by insider CHARNAS ROBERT
Post Analyst
Puma Biotechnology, Inc. (NASDAQ:PBYI) reached 85.92% versus a 1-year low price of $19.74. The stock was last seen 2.95% higher, reaching at $36.7 on Apr. 10, 2017. At recent session, the prices were hovering between $35.24 and $37.8. This company ...
Brokerages Anticipate Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $0.00The Cerbat Gem
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$1.86 Per ShareBBNS
Puma Biotechnology, Inc. (NYSE:PBYI): Trader Update on the ...Midway Monitor
Sports Perspectives -NYSE Journal (press release)
all 15 news articles »

Continue reading here:
Puma Biotechnology, Inc. (PBYI) recently sold by insider CHARNAS ROBERT - Post Analyst

Posted in Biotechnology | Comments Off on Puma Biotechnology, Inc. (PBYI) recently sold by insider CHARNAS ROBERT – Post Analyst

Brain cell therapy ‘promising’ for Parkinson’s disease – BBC News

Posted: April 11, 2017 at 3:41 pm


BBC News
Brain cell therapy 'promising' for Parkinson's disease
BBC News
Scientists believe they have found a way to treat and perhaps reverse Parkinson's disease, by making replacement cells to mend the damaged brain. They say human brain cells can be coaxed to take over the job of the ones that are destroyed in Parkinson's.
Cell Therapy 2.0: Reprogramming the Brain's Own Cells for Parkinson's TreatmentScientific American
Brain Cell Therapy Reverses Parkinson's-Like Symptoms In MiceHuffington Post UK
Brain cells reprogrammed to make dopamine, with goal of Parkinson's therapyThe San Diego Union-Tribune
STAT -NHS Choices
all 67 news articles »

Visit link:
Brain cell therapy 'promising' for Parkinson's disease - BBC News

Posted in Cell Therapy | Comments Off on Brain cell therapy ‘promising’ for Parkinson’s disease – BBC News

GE Healthcare Adds to Its Cell Therapy Portfolio by Acquiring Asymptote – Genetic Engineering & Biotechnology News

Posted: April 11, 2017 at 3:41 pm

GE Healthcare said today it has acquired Asymptote for an undisclosed price in a deal that the buyer said would strengthen its cell therapy portfolio with technologies designed to enable the cryopreservation of cellular materials.

Asymptote specializes in cryochain technology for sensitive cellular therapies, with the goal of significantly lowering the risk of contamination found in conventional processes.

The companys integrated suite of cryochain hardware, software, and consumables is designed to support cGMP and maintain the potency of cellular therapies by enabling ultra-low-temperature freezing during production, followed by thawing prior to administering to patients in clinical settings.

Asymptotes VIA FreezeTM range delivers liquid nitrogen-free cryopreservation, while the soon-to-be released VIA ThawTM series thaws deeply frozen cells using a dry conduction (water-free) process. The companys web-based my.Cryochain software platform is designed to support cell therapy companies as they scale their cryopreservation and thawing processes by synchronizing with the VIA Freeze and VIA Thaw products to standardize freezing and thawing programs across multiple sites, improving the visibility of remote processes.

Asymptotes high-quality offering takes us another step forward in our vision to industrialize cell therapy, and in providing reliable and high-quality services for our customers and patients around the world, Ger Brophy, Ph.D., general manager of GE Healthcares cell therapy business, said in a statement.

Added Asymptote founder and CEO John Morris, Ph.D.: The acquisition gives us the opportunity to reach a larger audience through the local specialist GE Cell Therapy team, provides us with a strong platform for our product launches, and allows us to significantly scale up our product development.

GE Healthcare reasons that demand for manufacturing and clinical delivery will increase as the cell therapy market grows and develops. The company cited statistics from the Alliance for Regenerative Medicine showing 804 clinical trials underway by the end of last year for cell therapies, as well as gene-modified cell therapies, gene therapies, and tissue-engineering therapies.

The acquisition of Asymptote is GE Healthcares latest move toward growing its cell therapy offerings. In July 2016, GE acquired Biosafe Group, a supplier of integrated cell bioprocessing systems, for an undisclosed sum. Three months earlier, GE Ventures teamed up with Mayo Clinic Ventures to launch Vitruvian Networks,a collaboration providing cloud-based software systems and manufacturing services for cell and gene therapies.

And in January 2016, GE Healthcare and the Government of Canada each committed C$20 million ($15 million) to launch the [emailprotected] Cell Therapy Centre of Excellence, created to promote new technologies for the production of cellular therapies in Toronto.

Read more:
GE Healthcare Adds to Its Cell Therapy Portfolio by Acquiring Asymptote - Genetic Engineering & Biotechnology News

Posted in Cell Therapy | Comments Off on GE Healthcare Adds to Its Cell Therapy Portfolio by Acquiring Asymptote – Genetic Engineering & Biotechnology News

Frequency Raises $32M in Series A to Develop Progenitor Cell Therapy for Hearing Loss – Genetic Engineering & Biotechnology News

Posted: April 11, 2017 at 3:41 pm

Frequency Therapeutics raised $32 million in a Series A financing to support development of its Progenitor Cell Activation (PCA) platform. The technology uses small molecules to trigger the division and differentiation of tissue-specific Lgr5+ progenitor cells and is initially being developed to generate new sensory cells in the inner ear as a treatment for noise-induced hearing loss. The Massachusetts-based firm says other potential applications of the platform could span skin disorders, muscle regeneration, and gastrointestinal diseases.

Frequencys Series A fundraising round was led by Cobro Ventures. Other investors included Morningside Ventures, Emigrant Capital, Korean Investment Partnership, Alexandria Real Estate Equities, and additional U.S. and international investors.

The PCA platform was developed by Robert Langer, Sc.D., and Jeffrey Karp, Ph.D., at the Massachusetts Institute of Technology (MIT), and Harvard Medical School. Frequency was established in 2015 to develop the platform for therapeutic indications and has an exclusive global license to relevant IP from MIT and Partners Healthcare. Bob Langer's and Jeff Karps vision is to gain much of the same effect as gene therapy and CRISPR by using small molecules, which we believe are safer and allow for easier delivery, stated Marc Cohen, co-founder of Cobro Ventures and chairman of Frequencys board of directors, which was established earlier this year. Our data is very compelling and we are excited to be moving to the clinic in the next 12 to 18 months.

Frequencys co-founders published in vitro research demonstrating use of their small-molecule approach to trigger the differentiation of Lgr5-expressing progenitor cells into sensory hair cells, in the February 21 issue of Cell Reports in a paper titled "Clonal Expansion of Lgr5-Positive Cells from Mammalian Cochlea and High-Purity Generation of Sensory Hair Cells."

Commenting on the initial, hearing loss indicaiton for the PCA platform, David Lucchino, Frequencys co-founder, president and CEO, added, With no effective therapy available, this presents an enormous market opportunity and we believe there is even broader potential in indications beyond hearing loss with the further development of the PCA platform.

Excerpt from:
Frequency Raises $32M in Series A to Develop Progenitor Cell Therapy for Hearing Loss - Genetic Engineering & Biotechnology News

Posted in Cell Therapy | Comments Off on Frequency Raises $32M in Series A to Develop Progenitor Cell Therapy for Hearing Loss – Genetic Engineering & Biotechnology News

Mesoblast takes off as cell therapy for heart failure passes interim test – FierceBiotech

Posted: April 11, 2017 at 3:41 pm

At the halfway point, a phase 3 trial of Mesoblast's off-the-shelf cell therapy for chronic heart failure is on track and should continue to completion, say advisers.

Shares in the Australian biotech hit a 12-month high on the update from the trial, which came after it enrolled 270 out of a planned total of 600 patients with moderate CHF andcruciallyrevealed no safety issues with Mesoblast's MPC-150-IM candidate.

The trial is still blinded so there is now way to tell if the therapy is having an effect, but it's a case of so far, so good, as the biotech looks ahead to completing the study next year.

The trial is seeing whether delivery of mesenchymal precursor cells (MPCs) via a catheter into the left ventricular heart muscle, to see if it can reduce non-fatal heart failure-related major adverse cardiac events (HF-MACE), such as death, needing a pacemaker implanted or undergoing a heart transplant.

Last year, Israeli drugmaker Teva returned rights to MPC-150-IM to Mesoblast, which it had inherited through its takeover of Cephalon. Mesoblast however decided to go it alone, a decision helped by a recent $40 million placement intended to help bring the CHF trial to fruition.

Analyst John Savin at Edison said in a recent note that the biotech may not have to wait for its own trial to complete before filing for U.S. approval. That could happen before the end of the year if a National Institutes of Health-sponsored trial of the therapy in end-stage heart failure patients hits the target.

The 159-patient NIH study is expected to complete enrolment in the first half andwith luckcould report top-line data before year-end, according to Savin. He reckons that could "lead to an application for accelerated approval" under the U.S. 21st Century Cures Act, which provides a speedy route to market for regenerative medicines.

"Passing this interim futility analysis for MPC-150-IM is an important milestone for Mesoblast and our cardiovascular disease program," commented CEO Silviu Itescu. "This validates our strategy and our prioritization of this valuable program." Analysts at Credit Suisse have previously suggested that that drug could be worth $4.1 billion in peak annual sales.

Mesoblast is not the only biotech looking at a stem cell approach to cardiovascular diseases. BioCardia is developing CardiAMP for CHF, reporting positive data from small phase 2 trial last year, while CardioCell presented mixed results on its candidate at the 2016 ESC Congress in Rome, and Celyad's C-Cure product failed to meet its objectives in its phase 3 CHART trial. Meanwhile, Belgium's TiGenix said recently its acute myocardial infarction therapy AlloCSC-01 hit its targets in a phase 1/2 trial.

The Australian biotech claimed an FDA green light to start trials of an MPC therapy given alongside corrective heart surgery for children with hypoplastic left heart syndrome (HLHS).

It's also in the build-up to a decision by option partner Mallinckrodt on its phase 3 MPC for chronic low back paindue in or before Septemberand a graft-versus-host disease (GVHD) candidate that should see pivotal results before year-end.

Follow this link:
Mesoblast takes off as cell therapy for heart failure passes interim test - FierceBiotech

Posted in Cell Therapy | Comments Off on Mesoblast takes off as cell therapy for heart failure passes interim test – FierceBiotech

Tackling Weight Loss and Diabetes With Video Chats – New York Times

Posted: April 11, 2017 at 3:40 pm


New York Times
Tackling Weight Loss and Diabetes With Video Chats
New York Times
About a year and a half ago, Robin Collier and her husband, Wayne, were like millions of other Americans: overweight and living with Type 2 diabetes. Despite multiple diets, the couple could not seem to lose much weight. Then Ms. Collier's doctor told ...

The rest is here:
Tackling Weight Loss and Diabetes With Video Chats - New York Times

Posted in Diabetes | Comments Off on Tackling Weight Loss and Diabetes With Video Chats – New York Times

Page 1,588«..1020..1,5871,5881,5891,590..1,6001,610..»